The evolution of aldosterone antagonists
Section snippets
Acknowledgements
The authors thank Xiao Hu and Suzhen Li of Pfizer, Inc. for performing the human steroid receptor selectivity studies.
References (39)
Mode of spirolactone action: competitive inhibition of aldosterone binding to kidney mineralocorticoid receptors
Biochem. Pharmacol.
(1968)- et al.
Efficacy and tolerability of eplerenone and losartan in hypertensive black patients and white patients
J. Am. Coll. Cardiol.
(2003) - et al.
Molecular modifications of anti-aldosterone compounds: effects on affinity of spirolactones for renal aldosterone receptors
Biochem. Pharmacol.
(1974) Recent studies with eplerenone, a novel selective aldosterone receptor antagonist
Curr. Opin. Pharmacol.
(2001)- et al.
Eplerenone, a selective aldosterone blocker, in mild to moderate hypertension
Am. J. Hypertens.
(2002) - et al.
Assessment of the novel selective aldosterone blocker eplerenone using ambulatory and clinical blood pressure in patients with systemic hypertension
Am. J. Cardiol.
(2003) Effect of enoterohepatic circulation on the pharmacokinetics of spironolactone in man
Naunyn-schmiedeberg’s Arch. Pharmacol.
(1977)- et al.
Remodeling of the right and left ventricles in experimental hypertension
Circ. Res.
(1990) - et al.
Relation of renin, angiotensin II, and experimental renal hypertension to aldosterone secretion
J. Clin. Invest.
(1961) - et al.
Steroidal aldosterone blockers. II
J. Org. Chem.
(1959)
Steroidal aldosterone blockers. I
J. Org. Chem.
(1959)
Involvement of CYP3A in the metabolism of eplerenone in humans and dogs: differential metabolism by CYP3A and CYP3A5
Drug Met. Dispos.
(2002)
Antiandrogenic effect of spirolactones: mechanism of action
Endocrinology
(1979)
SC-25152: A potent mineralocorticoid antagonist with reduced affinity for the 5α-dihydrotestosterone receptor of human and rat prostate
J. Clin. Endocrinal. Metab.
(1978)
SC-25152: A potent mineralocorticoid antagonist with decreased antiandrogenic activity relative to spironolactone
J. Pharmacol. Exp. Ther.
(1979)
Mechanisms regulating renin release
Physiol. Rev.
(1976)
Three new epoxy-spirolactone derivatives: characterization in vivo and in vitro
J. Pharm. Exp. Ther.
(1987)
Effect of a selective aldosterone receptor antagonist in myocardial infarction
Am. J. Physiol. Heart Circ. Physiol.
(2001)
Eplerenone: a selective aldosterone receptor antagonist (SARA)
Cardiovasc. Drug Rev.
(2001)
Cited by (150)
Renin Angiotensin Aldosterone System Blockers
2023, Hypertension: A Companion to Braunwald's Heart DiseaseDiuretic Agents
2022, Comprehensive PharmacologyThe challenging role of antiandrogens in the management of polycystic ovary syndrome
2022, Polycystic Ovary Syndrome: Challenging Issues in the Modern Era of Individualized MedicineRenin-Angiotensin-Aldosterone System
2022, Comprehensive Pharmacology
Copyright © 2003 Elsevier Ireland Ltd. All rights reserved.